EFNB2 and glioma: We identify the ZEB2-mediated suppression of ephrinB2 as a central regulatory pathway in governing tumour invasion and resistance to anti-angiogenic therapies in glioma, suggesting a therapeutic target that could help counteract the development of evasive resistance.